	Volume 2
	Pages 151 - 289
UNITED STA	ATES DISTRICT COURT
NORTHERN DI	STRICT OF CALIFORNIA
BEFORE THE HONORAB	BLE WILLIAM H. ORRICK, JUDGE
FINJAN, INC., a Delaware corporation,	
Plaintiff,	
VS.	No. C 14-1197 WHO
SOPHOS, INC., a Massachuset corporation,	ts
Defendant.	San Francisco, California Wednesday, September 7, 2016
TRANSCRI	PT OF PROCEEDINGS
APPEARANCES:	
For Plaintiff:	
KRA 990 Men BY: PAU LIS	MER, LEVIN, NAFTALIS & FRANKEL LLP Marsh Road Marsh R
401 San ву: JОН	N PIPER LLP B Street, Suite 1700 1 Diego, California 92101 IN ALLCOCK, ESQUIRE IN CUNNINGHAM, ESQUIRE PRYN RILEY GRASSÖ, ESQUIRE
Reported By: Katherine Pow Pamela A. Bat Official Repo	rell Sullivan, CSR #5812, RMR, CRR alo, CSR No. 3593, RMR, FCRR rters - U.S. District Court.

Vednesday, September 7, 2016 - Volume 2 PLAINTIFF'S WITNESSES	PAGE	VOI.
BIMS, HARRY		
(GWCRN) Direct Examination by Mr. Andre Cross-Examination by Mr. Allcock Redirect Examination by Mr. Andre	165 166 184 188	2 2 2 2
HARTSTEIN, PHIL	189	2
(GWORN) Direct Examination by Ms. Kobialka Cross-Examination by Mr. Allcock Redirect Examination by Ms. Kobialka Recross-Examination by Mr. Allcock	189 189 221 245 255	2 2 2 2 2
TOUBOUL, SHLOMO By Videotape Deposition (not reported)	256	2
KROLL, DAVID (1900m) Direct Examination by Mr. Hannah Cross-Examination by Mr. Allcock	257 259	2 2 2
STUTZ, DANIEL By Videotape Deposition (not reported)	271	2
HARRIS, MARK By Videotape Deposition (not reported)	271	2
HOWARD, FRASER By Videotape Deposition (not reported)	272	2
COLE, ERIC (SWOAN) Direct Examination by Mr. Andre	273 273	2 2

	EXHIBITS	IBITS		
TRIAL EXHIBITS		IDEN	EVID	VOL.
2			257	2
153			252	2
154			209	2
157			206	2
162			230	2
2034			272	2
2039			282	2
2525			217	2
2526			251	2
3045			243	2
4445			256	2

PROCEEDINGS

---000--
(Proceedings were heard out of presence of the jury:)

MR. ALLCOCK: Good morning, Your Honor.

THE COURT: Good morning. I understand we have an issue.

MR. ANDRE: Your Honor, just -- Paul Andre for Finjan.

Just a couple small issues.

We have plans this afternoon -- this morning to play some deposition designations, and we got some counters in last night from Sophos which we objected to, and we could not resolve them. I guess a good night's sleep resolved a lot of them, but there are still a couple that are not resolved.

The first one is a deposition of a Mr. Stutz, one of their

7:36 a.m.

The first one is a deposition of a Mr. Stutz, one of their engineers. We've agreed now to allow their -- some of their counters in because they withdrew the majority of them this morning, but I don't know logistically if we can get it done or not. I think our trial technician says he can do it at the break so I think we will be okay. I want to conditionally put that out there. We may have to object if we can't do the mechanics of the new cut. The way we do it is we prepare our original designations and we prepare a cut with their counters in, and now they've modified that again this morning. I think we can do it.



3

4

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

2

6

8

9

10

11

15

17

18

19

22

25

BY MR. ANDRE

2

4

5

6

7

8

9

10

11

12

13

14

15

16

23

24

25

6

7

8

9

10

11

12

13

14

15

16

17

18

19

21

22

23

24

Q. If you look at the front page, this is a Sophos presentation from January 2006. Did you review this document in preparing your analysis?

A. Yes, I did.

Q. And if you turn to page 3 of this document, there is a paragraph towards the bottom, next to the last paragraph, that states (as read):

"On the outside of the targets are UTM, Universal Threat Management. These products typically appeal to low end of the market, both in terms of customer size and what a customer is willing to pay. There are circumstances in which they may be a soft target, but generally a happy UTM customer will not be a realistic prospect for us."

Do you see that?

A. Yes, I do.

Q. Would you describe your understanding, what is being discussed in that paragraph in 2006?

A. Absolutely. So there's generally two types of solutions.
There's an endpoint solution, and there's a gateway device
known as a UTM, or Unified Threat Management, that sits on a
network between the internal computers and the Internet.

At this time in 2006, Sophos was still primary on endpoint. And here they're evaluating whether that gateway or UTM market is worth them getting into. And you can see, based

on some of their comments, that this really appeals to the low-end market. Typically, it's not going to be a realistic prospect.

They're still not convinced, in 2006, that gateway or UTM products are the right solution. They're still, sort of, saying, our endpoint solution is the way to go, and they're still hesitant and not sure that gateways are really going to solve customers' problems.

Q. If we turn to page 6 of this document, in the middle of the page there's a paragraph that talks about the advantages of the UTM market. It says (as read):

"Their advantages revolve around their ability to find malware. Tend to prove good malware detection. Some are better than others. Finjan in particular claimed to offer a completely unique approach to protection from web-borne malware, and seek to differentiate themselves from the mainstream anti-virus vendors. In fact, Finjan's approach is so unique they offer OEM virus engines, including ours just in case."

Would you describe what's being discussed in that paragraph in 2006.

A. So here they're talking about the new proactive way of solving security. And Sophos is clearly stating that Finjan has a completely unique approach.

So not only is Sophos fully aware of Finjan, but they are

COLE - DIRECT / ANDRE

285

COLE - DIRECT / ANDRE

286

associating that with that unique behavioral approach.

And then they go on to be fully aware that Finjan has patents in the space. So Sophos is saying, we know they have

patents; we know they have secret sauce; and they are considered, sort of, that leader in behavioral analysis.

Q. If we turn to what's already been admitted into evidence, Exhibit 2034.

(Document displayed.)

MR. ANDRE: I would like to have this published, Your Honor.

THE COURT: You may.

12 BY MR. ANDRE

O. Fast-forward almost five years, to 2011, an email chain.
And did you review this document in your analysis,

Dr. Cole?

16 A. Yes, I did.

Q. So if we go to the last -- the first email that's in the chain, it's on page 3.

(Document displayed.)

Q. This is dated Friday, March 11th, 2011. The subject is "Gartner SWG MQ second briefing."

Do you see that?

23 A. Yes, I do.

24 Q. What does "Gartner SWG MQ" stand for?

A. Gartner is an industry advisory company. They basically

saying they have a unique approach for solving this problem. And they're also going in to say that it's so unique, in terms of the behavioral analysis on the proactive piece, that they want to provide such a comprehensive solution that they also have traditional anti-virus that's reactive or signature based, that they're adding in so they will be able to catch both types of threats.

MR. ANDRE: Can we turn to the next page of this document.

(Document displayed.)

BY MR. ANDRE

Q. There is a paragraph that says:

"Purpose: Demonstrate behavior protection Finjan style."

Do you see that?

And then two paragraphs below that it says:

"They claim to have all sorts of patents and secret sauce that helps them detect bad behavior in code." Do you see that?

20 A. Yes, I do.

Q. Would you describe your understanding of what is being referred to there.

A. So here Sophos is not only recognizing that Finjan has a unique behavioral-based approach, but they're actually naming it after them. They're actually calling it the Finjan style,

DOCKET A L A R M